Clinical Trial Update: GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the addition of GLPG2737 to Orkambi in cystic fibrosis subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• GLPG2737
• ORKAMBI (lumacaftor and ivacaftor)

Snippet

Sponsor: Galapagos NV | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED